Literature DB >> 14341315

OSTEOGENIC SARCOMA IN CHILDREN.

R J MCKENNA, C P SCHWINN, N L HIGINBOTHAM.   

Abstract

One hundred and thirty children less than 16 years of age with pathologically verified osteogenic (skeletogenic) sarcoma were seen during a 30-year period (1925-1955) with a minimum follow-up of ten years. This age group represents 23.6 per cent of the authors' total experience with skeletogenic sarcoma. The absolute survival for the entire series was 18.5 per cent at five years and 16.2 per cent at ten years. No child with an osseous tumor elsewhere than in an extremity had longterm survival. Amputation was the only "curative" method of therapy; 23 per cent of patients so treated were alive at five years and 20 per cent were alive at ten years. Radiation was never "curative" when used as the sole method of therapy, and treatment failure was higher in the group of patients who were treated with preoperative irradiation and then amputation than in the group treated by amputation alone. Prognosis varied with the size of the tumor-the smaller the better. The most important factor in prognosis was the histologic subgrouping of osteogenic sarcoma. No evidence was found to support a belief that there are considerable differences between skeletogenic sarcomas in children and in adults.

Entities:  

Keywords:  ADOLESCENCE; AMPUTATION; BONE NEOPLASMS; CHILD; MORTALITY; SARCOMA, OSTEOGENIC

Mesh:

Year:  1965        PMID: 14341315      PMCID: PMC1515979     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  1 in total

1.  Osteogenic sarcoma; a critical analysis of 430 cases.

Authors:  M B COVENTRY; D C DAHLIN
Journal:  J Bone Joint Surg Am       Date:  1957-07       Impact factor: 5.284

  1 in total
  1 in total

1.  The survival of osteosarcoma patients 10 years old or younger is not worse than the survival of older patients: a retrospective analysis.

Authors:  Jun Ah Lee; Dong Ho Kim; Jung Sub Lim; Kyung Duk Park; Won Seok Song; Soo-Yong Lee; Dae-Geun Jeon
Journal:  Cancer Res Treat       Date:  2007-12-31       Impact factor: 4.679

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.